The m/m phase 2 results good but may not be good enough to get FDA EUA approval. In any case whether there is EUA approval or not we will likely have to go to phase 3 which means recruiting many more new patients than in phase 2. All of which will delay FDA acceptance for m/m considerably. I hope I am wrong and the FDA will grant acceptance and not require going to phase 3.

The problem with m/m is that patients often recover on their own so the leronlimab versus placebo effect is not as differentiated as hoped. .

The s/c phase 3 results will show a much better outcome. These patients do not progress on their own and often die. There should be an awesome difference in the leronlimab versus placebo outcomes. This will reinforce the already good m/m phase 2 results and should lead to immediate acceptance of both studies by the FDA.

It's time to more CYDY stockat it's reduced price.